This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
Immunovant, Inc. (IMVT) Up 9.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in first-quarter fiscal 2022 (ended Jun 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
Immunovant, Inc. (IMVT) Up 6.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Immunovant's (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401. Stock falls.
Immunovant, Inc. (IMVT) Down 12.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).
Immunovant (IMVT) Gains on a Potential Buyout by Roivant
by Zacks Equity Research
Immunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Roivant is a major stakeholder of Immunovant.
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.
What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings?
by Zacks Equity Research
Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.
Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will report earnings and revenues, and provide other pipeline updates when it releases fourth-quarter 2020 results.
Should You Buy Immunovant (IMVT) Ahead of Earnings?
by Zacks Equity Research
Immunovant (IMVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Acorda (ACOR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Acorda's (ACOR) upcoming Q4 earnings call, investor focus will be on the sales uptake of its Parkinson's disease drug, Inbrija.
Baudax (BXRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baudax (BXRX) will provide updates on earnings and revenues when it releases results for fourth-quarter 2020.
Immunovant (IMVT) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Immunovant (IMVT) has been struggling lately, but the selling pressure may be coming to an end soon.
scPharmaceuticals (SCPH) Plunges on Complete Response Letter
by Zacks Equity Research
scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult patients.
Coupa Software (COUP) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Coupa Software's (COUP) third-quarter fiscal 2021 results benefit from continued strength in adoption of the company's solutions including Business Spend Management and Coupa Pay.
Reata (RETA) Omaveloxolone Program Faces Delay on FDA Update
by Zacks Equity Research
Reata's (RETA) omaveloxolone development in Friedreich's Ataxia gets delayed further as FDA proposes additional exploratory analyses to support filing regulatory application for its approval.
Immunovant Up on Positive Data From Myasthenia Gravis Study
by Zacks Equity Research
Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.
Company News for Aug 26, 2020
by Zacks Equity Research
Companies in the news are: MDT, SJM, AAL, IMVT
Why Immunovant (IMVT) Stock Might be a Great Pick
by Zacks Equity Research
Immunovant (IMVT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Immunovant Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Immunovant
Immunovant (IMVT) Catches Eye: Stock Jumps 5%
by Zacks Equity Research
Immunovant (IMVT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.